Mattern Capital Management LLC Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Mattern Capital Management LLC lifted its position in Johnson & Johnson (NYSE:JNJFree Report) by 5.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,679 shares of the company’s stock after purchasing an additional 1,993 shares during the quarter. Mattern Capital Management LLC’s holdings in Johnson & Johnson were worth $6,492,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Rather & Kittrell Inc. increased its stake in shares of Johnson & Johnson by 2.0% during the second quarter. Rather & Kittrell Inc. now owns 2,909 shares of the company’s stock valued at $481,000 after purchasing an additional 58 shares in the last quarter. Capital Square LLC increased its position in Johnson & Johnson by 1.4% during the 2nd quarter. Capital Square LLC now owns 4,245 shares of the company’s stock valued at $703,000 after buying an additional 58 shares in the last quarter. Wagner Wealth Management LLC raised its stake in Johnson & Johnson by 1.3% during the second quarter. Wagner Wealth Management LLC now owns 4,543 shares of the company’s stock valued at $752,000 after buying an additional 59 shares during the last quarter. Chesapeake Wealth Management boosted its holdings in Johnson & Johnson by 0.7% in the second quarter. Chesapeake Wealth Management now owns 9,196 shares of the company’s stock worth $1,522,000 after acquiring an additional 60 shares in the last quarter. Finally, RPG Investment Advisory LLC grew its stake in shares of Johnson & Johnson by 1.2% in the second quarter. RPG Investment Advisory LLC now owns 4,876 shares of the company’s stock worth $807,000 after acquiring an additional 60 shares during the last quarter. 68.40% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.20% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $157.87 on Tuesday. The company has a market capitalization of $380.04 billion, a P/E ratio of 11.43, a P/E/G ratio of 2.63 and a beta of 0.53. Johnson & Johnson has a 1-year low of $144.95 and a 1-year high of $175.97. The firm’s 50 day simple moving average is $158.18 and its two-hundred day simple moving average is $158.62. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.21 and a quick ratio of 0.96.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The business had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. During the same quarter in the prior year, the business posted $2.35 EPS. Johnson & Johnson’s revenue for the quarter was down 9.7% compared to the same quarter last year. Research analysts expect that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be issued a $1.19 dividend. The ex-dividend date is Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio is presently 34.47%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on JNJ. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, November 17th. Raymond James raised their price target on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Wells Fargo & Company cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $170.00 to $163.00 in a research report on Wednesday, December 13th. UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $167.00 to $180.00 in a research note on Friday, December 1st. Finally, Morgan Stanley decreased their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Eight equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $176.14.

Check Out Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.